药明康德“卖子求生”?不,它正在下一盘更大的棋

Ofweek维科网
Feb 09

GLP-1减肥药卖疯了,带动整个多肽产业链火到不行,ADC(抗体偶联药物)领域融资和并购不断,被誉为抗癌药的“明日之星”。就在这波产业热潮里,中国CXO(医药外包)龙头药明康德,却干了一系列让人有点“看不懂”的操作,它开始频繁出售手里的资产和股权。2026年1月,药明康德发了份炸眼的业绩预告,2025年净利润预计约191.5亿,同比暴涨102.65%!但仔细一看,扣除非经常性损益的净利润是...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10